文献速递神经核医学

发作期脑灌注SPECT示踪剂选择:99mTc-HMPAO与99mTc-ECD无优劣证据

No Evidence to Favor 99mTc-HMPAO or 99mTc-ECD for Ictal Brain Perfusion SPECT for Identification of the Seizure Onset Zone.
PubMed 文献 · Clin Nucl Med · 2021-01-01

该研究回顾性纳入196例术前评估患者,分别使用稳定化99mTc-HMPAO(n=110)或99mTc-ECD(n=86)进行发作期脑灌注SPECT,由2名独立读者视觉判读确定致痫灶侧别与定位。两组示踪剂在侧别定侧比例上无显著差异(65.5% vs 72.1%,P=0.36);在62例颞叶癫痫术后Engel≤III级患者中,SPECT正确局部定侧灵敏度为63%。结论为无证据支持优先选用任一示踪剂。

要点

  • 99mTc-HMPAO与99mTc-ECD发作期SPECT定侧比例无显著差异(65.5% vs 72.1%,P=0.36)。
  • 62例颞叶癫痫术后Engel≤III级患者中,SPECT正确局部定侧灵敏度为63%。
  • 两组在年龄、性别、病程、发作频率、既往脑手术史及术前MRI findings上匹配良好。

核心结论

  • 本研究未提供证据支持在发作期脑灌注SPECT识别致痫灶时优先选用99mTc-HMPAO或99mTc-ECD。

研究设计与样本

  • 回顾性纳入临床常规中接受发作期灌注SPECT的196例患者,使用稳定化99mTc-HMPAO(n=110)或99mTc-ECD(n=86)。
  • 由2名独立读者基于SPECT图像视觉判读共识获得致痫灶侧别与定位。

主要发现

  • 99mTc-HMPAO组与99mTc-ECD组在年龄、性别、首次发作年龄、病程、发作频率、既往脑手术史及术前MRI findings方面匹配良好。
  • 99mTc-HMPAO与99mTc-ECD的发作期SPECT定侧比例无显著差异(65.5% vs 72.1%,P=0.36)。
  • 在62例颞叶癫痫且术后12个月Engel≤III级患者中,发作期灌注SPECT(不区分示踪剂)正确局部定侧致痫灶的灵敏度为63%。

关键数值与推荐

  • 发作期SPECT定侧比例:99mTc-HMPAO组65.5%,99mTc-ECD组72.1%,P=0.36。
  • 颞叶癫痫术后Engel≤III级患者中,SPECT正确局部定侧灵敏度为63%。

临床怎么用

  • 在术前评估中,若标准线索不确定或不一致,发作期脑灌注SPECT可辅助致痫灶定侧定位,示踪剂选择不必强求某一品种。

局限性

  • 本研究为回顾性设计,示踪剂分组非随机,可能受临床常规选择偏倚影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Ictal brain perfusion SPECT with the tracer 99mTc-HMPAO or 99mTc-ECD is widely used for identification of the epileptic seizure onset zone (SOZ) in presurgical evaluation if standard pointers are uncertain or inconsistent. For both tracers, there are theoretical arguments to favor it over the other for this task. The aim of this study was to compare the performance of ictal brain perfusion SPECT between 99mTc-HMPAO and 99mTc-ECD in a rather large patient sample. PATIENTS AND METHODS: The study retrospectively included 196 patients from clinical routine in whom ictal perfusion SPECT had been performed with stabilized 99mTc-HMPAO (n = 110) or 99mTc-ECD (n = 86). Lateralization and localization of the SOZ were obtained by the consensus of 2 independent readers based on visual inspection of the SPECT images. RESULTS: The 99mTc-HMPAO group and the 99mTc-ECD group were well matched with respect to age, sex, age at first seizure, duration of disease, seizure frequency, history of previous brain surgery, and findings of presurgical MRI. The proportion of lateralizing ictal SPECT did not differ significantly between 99mTc-HMPAO and 99mTc-ECD (65.5% vs 72.1%, P = 0.36). Sensitivity of ictal perfusion SPECT (independent of the tracer) for correct localization of the SOZ in 62 patients with temporal lobe epilepsy and at least worthwhile improvement (Engel scale ≤ III) 12 months after temporal epilepsy surgery was 63%. CONCLUSIONS: This study does not provide evidence to favor 99mTc-HMPAO or 99mTc-ECD for identification of the SOZ by ictal perfusion SPECT.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Jaber M, Taherpour J, Voges B, et al. No Evidence to Favor 99mTc-HMPAO or 99mTc-ECD for Ictal Brain Perfusion SPECT for Identification of the Seizure Onset Zone. Clin Nucl Med. 2021. PMID: 34238801. doi:10.1097/RLU.0000000000003791

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。